The effects of neuropeptides on mucous glycoprotein secretion from human nasal mucosa in vitro.
The role of neuropeptides in the regulation of macromolecule secretion from human nasal mucosa is incompletely understood. Previous in vitro explant culture studies have demonstrated the effects of neuropeptides on lactoferrin release from serous cells and 3H-glucosamine labeled respiratory glycoconjugate secretion from mucus-containing cells. The generation of a new monoclonal antibody, 7F10, has led to the development of an ELISA for high molecular weight respiratory mucous glycoproteins (MGP). This ELISA was used to measure the ability of sensory, parasympathetic and sympathetic neuropeptides to stimulate MGP release from human nasal mucosal fragments in short term explant culture in vitro. Significant MGP release was stimulated by the sensory neuropeptides gastrin releasing peptide (10 microM GRP: 10.6% +/- 2.4% increase, n = 8, P less than 0.01 vs. control), substance P (1 microM SP: 12.5% +/- 5.4%, n = 11, P less than 0.05), neurokinin A (1 microM NKA: 17.8 +/- 4.3%, n = 6, P less than 0.01), while calcitonin gene related peptide (CGRP) was without effect. Vasoactive intestinal peptide (VIP), a neurotransmitter from parasympathetic nerves, induced significant dose dependent MGP secretion, but had no additive or inhibitory interaction with methacholine-induced secretion. Neuropeptide Y (NPY), present in sympathetic nerves, had no effect on MGP secretion. These observations correlate with the effects of neuropeptides on serous cell lactoferrin secretion, and the presence of specific GRP, SP, and VIP binding sites on human nasal submucosal glands that have been detected by autoradiography. GRP and tachykinins (SP and NKA) from sensory nerves, and VIP released during parasympathetic reflexes may significantly stimulate mucous and serous cell secretion from human nasal mucosa in vivo.
Mullol
J
J
Allergic Diseases Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892.
Rieves
R D
RD
Baraniuk
J N
JN
Lundgren
J D
JD
Mérida
M
M
Hausfeld
J H
JH
Shelhamer
J H
JH
Kaliner
M A
MA
D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D019886:Gastrin-Releasing Peptide; D006023:Glycoproteins / Q000378:metabolism*; D016210:Methacholine Chloride / Q000494:pharmacology; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism*; D015288:Neurokinin A / Q000494:pharmacology; D009478:Neuropeptide Y / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010455:Peptides / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D006023:Glycoproteins; D009478:Neuropeptide Y; D009479:Neuropeptides; D010455:Peptides; D016210:Methacholine Chloride; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D019886:Gastrin-Releasing Peptide; D015288:Neurokinin A; D015740:Calcitonin Gene-Related Peptide